英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

07630 英派药业-B

未开盘 07-24 16:08:04

11.500

-0.560

-4.64%

最高12.490	最低11.500	成交量27.58万
今开12.220	昨收12.060	日振幅8.21%
总市值32.48亿	流通市值32.48亿	总股本2.82亿
成交额330.17万	换手率0.10%	流通股本2.82亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"07630","market":"HK","secType":"STK","nameCN":"英派药业-B","latestPrice":11.5,"timestamp":1784880484038,"preClose":12.06,"halted":0,"volume":275800,"delay":0,"changeRate":-0.046434494195688264,"floatShares":282461530,"shares":282461530,"eps":-1.4999228143698486,"marketStatus":"未开盘","change":-0.56,"latestTime":"07-24 16:08:04","open":12.22,"high":12.49,"low":11.5,"amount":3301690,"amplitude":0.08209,"askPrice":11.5,"askSize":2600,"bidPrice":11.4,"bidSize":1200,"shortable":0,"etf":0,"ttmEps":-1.343855956460707,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785115800000},"marketStatusCode":0,"adr":0,"listingDate":1778601600000,"exchange":"SEHK","adjPreClose":12.06,"openAndCloseTimeList":[[1784856600000,1784865600000],[1784869200000,1784880000000]],"volumeRatio":0.5503671773576089,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/07630","defaultTab":"news","newsList":[{"id":"2652684382","title":"英派药业-B(07630)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=2652684382","media":"智通财经网","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652684382?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:38","pubTimestamp":1784504331,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，三个主要管线项目的最新临床数据已获接受于2026年欧洲肿瘤内科学会大会作壁报展示。欧洲肿瘤内科学会大会是全球肿瘤学领域最具影响力的学术会议之一，本年度的大会将于2026年10月23日至27日在西班牙马德里举行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469474.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B(07630)：多项研究结果摘要获接受于2026年欧洲肿瘤内科学会大会作壁报展示","news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1176490454","title":"英派药业-B（07630）三项管线最新数据获2026年ESMO大会壁报展示","url":"https://stock-news.laohu8.com/highlight/detail?id=1176490454","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1176490454?lang=zh_cn&edition=full","pubTime":"2026-07-20 07:35","pubTimestamp":1784504139,"startTime":"0","endTime":"0","summary":"2026年7月20日，英派药业-B发布自愿公告称，公司三项核心管线项目的最新临床研究数据获欧洲肿瘤内科学会2026年大会接纳，并将在10月23日至27日于西班牙马德里举行的会议上以壁报形式展示。其欧洲上市许可申请已于2025年8月获欧洲药品管理局受理，预计2026年下半年可获批。英派药业-B提示，根据香港联交所《上市规则》第18A.05条，公司无法保证塞纳帕利在新增适应症的开发一定成功，也无法保证IMP1734及IMP1707最终获批上市。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193557412","title":"英派药业-B（07630）拟设立股份奖励计划 并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=1193557412","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193557412?lang=zh_cn&edition=full","pubTime":"2026-07-10 21:30","pubTimestamp":1783690255,"startTime":"0","endTime":"0","summary":"2026年7月10日，英派药业-B公告称，董事会已决议向股东大会提呈两项议案：一是建议采纳《2026年股份奖励计划》，二是建议修订公司组织章程细则。上述两项议案均须经公司股东在临时股东大会上审议并获通过后方可生效。截至公告披露日，英派药业-B董事会成员包括：执行董事蔡遂雄博士、田野博士、马宁女士；非执行董事徐聪博士、Qiang Xu博士、刘涛先生；独立非执行董事郭明博士、萧志雄先生、邵黎明博士。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142925850","title":"英派药业-B（07630）将于2026年7月27日召开首次临时股东会并暂停过户","url":"https://stock-news.laohu8.com/highlight/detail?id=1142925850","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142925850?lang=zh_cn&edition=full","pubTime":"2026-07-08 19:20","pubTimestamp":1783509637,"startTime":"0","endTime":"0","summary":"英派药业-B7月8日公告，公司拟于2026年7月27日（星期一）举行2026年第一次临时股东会。为确定股东出席及投票资格，公司将于2026年7月22日（星期三）至2026年7月27日（星期一）暂停办理股份过户登记手续。在2026年7月27日名列股东名册的股东，或其委任代表或获授权公司代表，均可出席并投票。根据公告披露，董事会目前由3名执行董事、3名非执行董事及3名独立非执行董事组成。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649702626","title":"Tencent Holdings Limited增持英派药业-B(07630)35万股 每股作价约36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649702626","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649702626?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，6月30日，Tencent Holdings Limited增持英派药业-B(07630)35万股，每股作价36.1719港元，总金额约为1266.02万港元。增持后最新持股数目约为1988.05万股，持股比例为7.04%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1463687.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4504","07630","BK4581","BK4550","BK4585","EWH","IEMG","BK4588","EDZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649626700","title":"Tencent Holdings Limited增持英派药业-B(07630.HK)35万股 每股作价约36.17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2649626700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649626700?lang=zh_cn&edition=full","pubTime":"2026-07-06 19:36","pubTimestamp":1783337776,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117782722","title":"英派药业-B6月股份变动月报：注册股本增至282,461,530股","url":"https://stock-news.laohu8.com/highlight/detail?id=1117782722","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117782722?lang=zh_cn&edition=full","pubTime":"2026-07-06 17:11","pubTimestamp":1783329061,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司（英派药业-B, 07630）于2026年7月6日披露了截至2026年6月30日的股份变动月报。报告期内，公司完成了超额配股权益的行使，新发行并配发6,296,400股H股，使注册股本由276,165,130股增至282,461,530股。\n本月无股份购回、注销及库藏股变动，也未披露任何新的股份期权或股权激励计划。公司表示已遵守香港联合交易所有限公司《上市规则》及相关法律法规要求。公告由执行董事兼首席执行官蔡遂雄签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453054","title":"55家公司港股通新贵即将喜迎北水流入 入通门槛或已抬升至102.67亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453054","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647453054?lang=zh_cn&edition=full","pubTime":"2026-07-01 10:09","pubTimestamp":1782871774,"startTime":"0","endTime":"0","summary":"核心规则：市值门槛动态调整截至2026年6月30日，港股通实际纳入门槛已升至102.67亿，剔除门槛达66.89亿。这一指标直接决定了个股在指数中的权重与港股通资格。对于不同上市时长的公司，要求有所不同：对于上市公司而言，维持日均万五左右的换手率是保住港股通资格的关键。数据截止日为每年的6月30日和12月31日，这也是上市公司\"冲关\"港股通的关键时间窗口。","market":"hk","thumbnail":"https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/0cf777090175126e4590c3b8afdfe41e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461288.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["07630","01651","06636","09637","01866","02723","03887","01286","00100","02696","01440","03388","06938","01133","BK4588","00412","02672","00863","01779","06656","BK4585","00600","03277","07688","01081","03625","09630","02526","01236","02726","02553","02335","01672","02670","03355","06106","02616","00340","01879","02142","02632","02729","03310","03661","06675","01511","06658","01191","02272","06872","00376","01956","01392","01021","01609","00068","07666"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2647770353","title":"股东施毅增持英派药业-B(07630)2.00万股 每股作价约35.94港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647770353","media":"智通财经网","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647770353?lang=zh_cn&edition=full","pubTime":"2026-06-29 21:30","pubTimestamp":1782739825,"startTime":"0","endTime":"0","summary":"香港联交所最新数据显示，6月24日，股东施毅增持英派药业-B(07630)2万股，每股作价35.9388港元，总金额约为71.88万港元。","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260629/20260629213043_51705.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1460671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","07630","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106328124","title":"英派药业-B：6月10日因超额配股权行使发行629.64万股H股，涉资约1.27亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1106328124","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106328124?lang=zh_cn&edition=full","pubTime":"2026-06-11 06:12","pubTimestamp":1781129528,"startTime":"0","endTime":"0","summary":"2026年6月11日，南京英派药业股份有限公司（英派药业-B，股票代码：07630）发布公告，披露于2026年6月10日因超额配股权获悉数行使，新增发行并配发6,296,400股H股，占发行前已发行股本约2.3%。每股发行价为20.1港元，合计涉资约1.27亿港元。\n本次发行完成后，公司已发行股本由276,165,130股增至282,461,530股。公司确认本次发行已遵循香港联交所证券上市规则及相关法律法规规定，并获得董事会正式授权。上述公告由公司执行董事兼首席执行官蔡遂雄签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"英派药业-B：6月10日因超额配股权行使发行629.64万股H股，涉资约1.27亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642471572","title":"英派药业-B(07630)因超额配股权获行使而发行629.64万股H股","url":"https://stock-news.laohu8.com/highlight/detail?id=2642471572","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642471572?lang=zh_cn&edition=full","pubTime":"2026-06-11 06:10","pubTimestamp":1781129453,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年6月10日因超额配股权获悉数行使而发行及配发629.64万股H股股份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452889.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641107217","title":"英派药业-B(07630)：悉数行使超额配股权、稳定价格行动及稳定价格期结束","url":"https://stock-news.laohu8.com/highlight/detail?id=2641107217","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641107217?lang=zh_cn&edition=full","pubTime":"2026-06-08 16:53","pubTimestamp":1780908808,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B 发布公告，有关全球发售的稳定价格期于2026年6月7日(星期日)结束。于稳定价格期，稳定价格操作人并无出于稳定价格的目的在市场上购入或出售任何H股。紧随超额配股权获悉数行使及稳定价格期结束后，本公司将继续遵守上市规则第19A.28B条的公众持股量规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451397.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2641760148","title":"英派药业-B(07630)：超额配股权获悉数行使","url":"https://stock-news.laohu8.com/highlight/detail?id=2641760148","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641760148?lang=zh_cn&edition=full","pubTime":"2026-06-05 20:54","pubTimestamp":1780664056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)公布，招股章程所述超额配股权已于2026年6月5日(星期五)获整体协调人(为其本身及代表国际包销商)悉数行使，涉及合共629.64万股H股，占于任何超额配股权获行使前全球发售项下初步可供认购的发售股份总数约15%。因超额配股权获行使而将予发行的H股(“超额配发股份”)将由本公司按每股H股 20.10港元发行及配发。超额配发股份将用于加快向同意延迟交付其根据全球发售认购的相关H股的承配人交付部分H股。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450968.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["07630","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193760729","title":"英派药业-B5月股份变动月报：股本保持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1193760729","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1193760729?lang=zh_cn&edition=full","pubTime":"2026-06-04 18:11","pubTimestamp":1780567895,"startTime":"0","endTime":"0","summary":"南京英派药业股份有限公司于2026年6月4日发布截至2026年5月31日止的股份变动月报。公告显示，公司法定/注册股本在报告期内无变化，截至2026年5月31日止的法定/注册股本数为人民币276,165,130元；普通股H股的已发行股本维持在276,165,130股，未发生任何新增发行、回购或转换注销。公司5月内也未发生任何库存股变动，库存股份数仍为0股。根据本次月报，英派药业-B的股本结构自上市以来保持稳定。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130218577","title":"英派药业-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1130218577","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130218577?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:36","pubTimestamp":1780483018,"startTime":"0","endTime":"0","summary":"英派药业-B6月3日发布公告，董事会已获一般性授权，可在香港联合交易所有限公司按不超过公司已发行H股总数10%的规模进行股份购回。现有发行股本约2.76亿股H股，授权范围最高可达约2761.65万股，购回事宜尚需于2026年6月25日召开的年度股东大会上审议并生效。根据公告，英派药业-B上市后，于2026年5月13日至6月初期间，H股最高价为每股47.98港元，最低为28.20港元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"英派药业-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981904","title":"英派药业-B(07630)：IMP1734于2026年ASCO年会公布I/II期临床数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981904","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640981904?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:37","pubTimestamp":1780274251,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英派药业-B(07630)发布公告，于2026年5月29日至6月2日在美国芝加哥举办的2026年美国临床肿瘤学会(ASCO)年会上，以壁报形式发布高选择性PARP1抑制剂IMP1734(亦称为EIK1003)的最新I/II期临床数据。该壁报(摘要编号：#3102)展示了IMP1734单药治疗及联合紫杉醇治疗晚期实体瘤的安全性与初步有效性数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448253.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121551346","title":"异动解读 | 英派药业-B盘中大涨15.59%，受技术反弹、内部增持及核心产品纳入医保等多重利好推动","url":"https://stock-news.laohu8.com/highlight/detail?id=1121551346","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1121551346?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:15","pubTimestamp":1779419700,"startTime":"0","endTime":"0","summary":"英派药业-B今日盘中大涨15.59%，引起了市场的广泛关注。消息面上，此次上涨可能受到多重因素驱动。其次，公司关联方在上市日进行了大额增持，释放了内部对公司前景的信心信号。更重要的是，公司的核心产品塞纳帕利已被纳入国家医保目录并从今年开始执行医保价格，这有望显著推动其营收放量。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的生物技术公司，目前已进入商业化阶段。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103271327","title":"异动解读｜英派药业-B盘中上涨13.17%，上市初期获利回吐后快速反弹获资金回补","url":"https://stock-news.laohu8.com/highlight/detail?id=1103271327","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103271327?lang=zh_cn&edition=full","pubTime":"2026-05-22 11:13","pubTimestamp":1779419602,"startTime":"0","endTime":"0","summary":"5月22日，英派药业-B盘中上涨13.17%，报35.58港元，成交额871.6万港元。消息面上，公司于5月13日以每股20.10港元登陆港交所，首日大涨108.26%，此后经历获利回吐股价自高点回落超15%，昨日一度下跌逾5%后今日迎来强势反弹。英派药业是一家专注于基于合成致死机制的精准抗癌疗法研发的商业化阶段生物技术公司，核心产品塞纳帕利已在中国获批上市，产品管线涵盖PARP1/2、PARP1、ATR、WEE1等多个靶点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161371010","title":"异动解读 | 英派药业-B盘中大跌5.18%，上市后冲高回落现获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1161371010","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1161371010?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:31","pubTimestamp":1779330713,"startTime":"0","endTime":"0","summary":"英派药业-B(07630)今日盘中股价大幅下挫5.18%，引发市场关注。消息面上，公司近期登陆港交所后股价经历了大幅上涨，自高点回落幅度已超过15%，短期获利盘兑现压力开始显现。此外，公司目前仍处于亏损阶段，2025年净亏损约2.96亿元，而营收仅为3825万元，尚无法覆盖高强度的研发投入，基本面对当前较高估值的支撑力度有限，可能也是股价承压的因素之一。英派药业是一家基于合成致死机制的精准抗癌疗法企业，其核心产品塞纳帕利已在中国获批上市并纳入医保目录。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118559761","title":"异动解读｜英派药业-B盘中下跌5.77%，上市后冲高回落或现获利回吐压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1118559761","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118559761?lang=zh_cn&edition=full","pubTime":"2026-05-21 10:30","pubTimestamp":1779330603,"startTime":"0","endTime":"0","summary":"5月21日，英派药业-B盘中下跌5.77%，报35.28港元，成交额511.1万港元。消息面上，公司于5月13日以每股20.10港元定价登陆港交所，首日收报41.86港元，较招股价涨108.26%，此后连续多日维持高位震荡。经历上市后大幅上涨，股价自高点回落幅度已超15%，短期获利盘兑现压力显现。值得关注的是，公司仍处亏损阶段，2025年净亏损约2.96亿元，营收仅3825万元，尚无法覆盖高强度研发投入，基本面对高估值的支撑力度有限。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["07630"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.impacttherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.1792},{"period":"1month","weight":-0.6811},{"period":"3month","weight":-0.4279},{"period":"ytd","weight":-0.4279}],"compareEarnings":[{"period":"1week","weight":0.0163},{"period":"1month","weight":0.0662},{"period":"3month","weight":-0.0391},{"period":"6month","weight":-0.0668},{"period":"1year","weight":-0.0274},{"period":"ytd","weight":-0.026}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"南京英派药业股份有限公司是一家主要从事生物技术研发和商业化的中国公司。该公司处于商业化阶段。该公司致力于在全球范围内推进基于合成致死（SL）机制的精准抗癌疗法。该公司自主研发的核心产品塞纳帕利已在中国获批上市，作为卵巢癌（OC）一线维持疗法。该公司正在研发的产品管线包PARP1/2、PARP1、ATR、WEE1、PKMYT1/WEE1、DHX9、ATM、USP1及CHK1/2等。","exchange":"SEHK","name":"英派药业-B","nameEN":"IMPACT THERAP-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英派药业-B,07630,英派药业-B股票,英派药业-B股票老虎,英派药业-B股票老虎国际,英派药业-B行情,英派药业-B股票行情,英派药业-B股价,英派药业-B股市,英派药业-B股票价格,英派药业-B股票交易,英派药业-B股票购买,英派药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英派药业-B(07630)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英派药业-B(07630)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}